HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway

Resistance of glioblastoma multiforme to radiotherapy poses a major clinical challenge. Farnesyltransferase inhibitors (FTI), such as R115777, have potential to increase radiotherapeutic benefit in this disease, although their mechanism of action is unclear. In our study with eight glioblastoma mult...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2006-07, Vol.66 (13), p.6756-6762
Hauptverfasser: Wang, Chun-Chieh, Liao, Yu-Pei, Mischel, Paul S, Iwamoto, Keisuke S, Cacalano, Nicholas A, McBride, William H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 6762
container_issue 13
container_start_page 6756
container_title Cancer research (Chicago, Ill.)
container_volume 66
creator Wang, Chun-Chieh
Liao, Yu-Pei
Mischel, Paul S
Iwamoto, Keisuke S
Cacalano, Nicholas A
McBride, William H
description Resistance of glioblastoma multiforme to radiotherapy poses a major clinical challenge. Farnesyltransferase inhibitors (FTI), such as R115777, have potential to increase radiotherapeutic benefit in this disease, although their mechanism of action is unclear. In our study with eight glioblastoma multiforme cell lines, the most sensitive ones underwent cell cycle arrest in response to FTI treatment. Radiosensitization by FTIs, however, seemed to involve other pathways. If R115777 treatment was initiated < 6 hours before irradiation, all eight glioblastoma multiforme lines were radiosensitized. However, if the time between drug and radiation was extended to 24 hours, cells harboring wild type but not mutated p53 were able to counteract drug-induced radiosensitization. The involvement of the p53/p21 pathway in the development of resistance was confirmed by showing that U87 cells transfected with human papillomavirus E6 to block p53 or interfering RNA to inhibit p21 stayed radiosensitive for 24 hours after drug treatment. The time dependency of R115777-induced radiosensitization suggested that the initial FTI target for early radiosensitization was short-lived, and that a p21-directed pathway restored resistance. Consideration of prenylated molecules that could potentially be involved led us to consider HDJ-2, a co-chaperone of heat shock protein 70. This hypothesis was strengthened by finding that cellular radiosensitivity was increased by genetic inhibition of HDJ-2, whereas overexpression conferred radioresistance. Importantly, irradiation of cells caused HDJ-2 to migrate from the cytoplasm to the nucleus, and this migration was inhibited by prior FTI treatment. These results have clinical relevance in that they help explain the variability in responses to FTIs that occurs following radiotherapy and elucidate some of the reasons for the complexity underlying FTI-induced radiosensitization.
doi_str_mv 10.1158/0008-5472.CAN-06-0185
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68605481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68605481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-7940be605076caca213404d33d8138cd347f61fa5fa64ea90adc7386b8771413</originalsourceid><addsrcrecordid>eNqFkc9O3DAQh62qqGyBR6DyqbeAJ_7LES20tEIgIe7WJLFZoyQOtldo-yg8bZOyao89eSx985sZfYScAjsDkOacMWYqKXR9tr68q5iqGBj5gaxAclNpIeRHsvrLHJLPOT_PXwlMfiKHoAwYJWFF3m6uflY1xUyRFkxPrlAfE03YhZjdmEMJv7CEONLo6VMfYtNjLnFAOmz7EmZ2cLR1fZ9ps6Nl46jHNLq860vCMXuXMDsaxk1oQpmDH-bltdYUx-4PnWLvluilniQ_n2qgE5bNK-6OyYHHPruT_XtEHr9dP65vqtv77z_Wl7dVK4wslb4QrHGKSaZViy3WwAUTHeedAW7ajgvtFXiUHpVweMGwazU3qjFagwB-RL6-x04pvmxdLnYIebkIRxe32SozZwvzfxB0rZbrZlC-g22KOSfn7ZTCgGlngdlFnl3E2EWMneVZpuwib-77sh-wbQbX_eva2-K_AaWPlY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17261157</pqid></control><display><type>article</type><title>HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Wang, Chun-Chieh ; Liao, Yu-Pei ; Mischel, Paul S ; Iwamoto, Keisuke S ; Cacalano, Nicholas A ; McBride, William H</creator><creatorcontrib>Wang, Chun-Chieh ; Liao, Yu-Pei ; Mischel, Paul S ; Iwamoto, Keisuke S ; Cacalano, Nicholas A ; McBride, William H</creatorcontrib><description>Resistance of glioblastoma multiforme to radiotherapy poses a major clinical challenge. Farnesyltransferase inhibitors (FTI), such as R115777, have potential to increase radiotherapeutic benefit in this disease, although their mechanism of action is unclear. In our study with eight glioblastoma multiforme cell lines, the most sensitive ones underwent cell cycle arrest in response to FTI treatment. Radiosensitization by FTIs, however, seemed to involve other pathways. If R115777 treatment was initiated &lt; 6 hours before irradiation, all eight glioblastoma multiforme lines were radiosensitized. However, if the time between drug and radiation was extended to 24 hours, cells harboring wild type but not mutated p53 were able to counteract drug-induced radiosensitization. The involvement of the p53/p21 pathway in the development of resistance was confirmed by showing that U87 cells transfected with human papillomavirus E6 to block p53 or interfering RNA to inhibit p21 stayed radiosensitive for 24 hours after drug treatment. The time dependency of R115777-induced radiosensitization suggested that the initial FTI target for early radiosensitization was short-lived, and that a p21-directed pathway restored resistance. Consideration of prenylated molecules that could potentially be involved led us to consider HDJ-2, a co-chaperone of heat shock protein 70. This hypothesis was strengthened by finding that cellular radiosensitivity was increased by genetic inhibition of HDJ-2, whereas overexpression conferred radioresistance. Importantly, irradiation of cells caused HDJ-2 to migrate from the cytoplasm to the nucleus, and this migration was inhibited by prior FTI treatment. These results have clinical relevance in that they help explain the variability in responses to FTIs that occurs following radiotherapy and elucidate some of the reasons for the complexity underlying FTI-induced radiosensitization.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/0008-5472.CAN-06-0185</identifier><identifier>PMID: 16818651</identifier><language>eng</language><publisher>United States</publisher><subject>Cell Cycle - drug effects ; Cell Cycle - radiation effects ; Cell Line, Tumor ; Combined Modality Therapy ; Cyclin-Dependent Kinase Inhibitor p21 - metabolism ; Enzyme Inhibitors - pharmacology ; Farnesyltranstransferase - antagonists &amp; inhibitors ; Glioblastoma - drug therapy ; Glioblastoma - enzymology ; Glioblastoma - pathology ; Glioblastoma - radiotherapy ; HSP40 Heat-Shock Proteins - metabolism ; HSP40 Heat-Shock Proteins - physiology ; Human papillomavirus ; Humans ; Quinolones - pharmacology ; Radiation-Sensitizing Agents - pharmacology ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Cancer research (Chicago, Ill.), 2006-07, Vol.66 (13), p.6756-6762</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-7940be605076caca213404d33d8138cd347f61fa5fa64ea90adc7386b8771413</citedby><cites>FETCH-LOGICAL-c485t-7940be605076caca213404d33d8138cd347f61fa5fa64ea90adc7386b8771413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16818651$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Chun-Chieh</creatorcontrib><creatorcontrib>Liao, Yu-Pei</creatorcontrib><creatorcontrib>Mischel, Paul S</creatorcontrib><creatorcontrib>Iwamoto, Keisuke S</creatorcontrib><creatorcontrib>Cacalano, Nicholas A</creatorcontrib><creatorcontrib>McBride, William H</creatorcontrib><title>HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Resistance of glioblastoma multiforme to radiotherapy poses a major clinical challenge. Farnesyltransferase inhibitors (FTI), such as R115777, have potential to increase radiotherapeutic benefit in this disease, although their mechanism of action is unclear. In our study with eight glioblastoma multiforme cell lines, the most sensitive ones underwent cell cycle arrest in response to FTI treatment. Radiosensitization by FTIs, however, seemed to involve other pathways. If R115777 treatment was initiated &lt; 6 hours before irradiation, all eight glioblastoma multiforme lines were radiosensitized. However, if the time between drug and radiation was extended to 24 hours, cells harboring wild type but not mutated p53 were able to counteract drug-induced radiosensitization. The involvement of the p53/p21 pathway in the development of resistance was confirmed by showing that U87 cells transfected with human papillomavirus E6 to block p53 or interfering RNA to inhibit p21 stayed radiosensitive for 24 hours after drug treatment. The time dependency of R115777-induced radiosensitization suggested that the initial FTI target for early radiosensitization was short-lived, and that a p21-directed pathway restored resistance. Consideration of prenylated molecules that could potentially be involved led us to consider HDJ-2, a co-chaperone of heat shock protein 70. This hypothesis was strengthened by finding that cellular radiosensitivity was increased by genetic inhibition of HDJ-2, whereas overexpression conferred radioresistance. Importantly, irradiation of cells caused HDJ-2 to migrate from the cytoplasm to the nucleus, and this migration was inhibited by prior FTI treatment. These results have clinical relevance in that they help explain the variability in responses to FTIs that occurs following radiotherapy and elucidate some of the reasons for the complexity underlying FTI-induced radiosensitization.</description><subject>Cell Cycle - drug effects</subject><subject>Cell Cycle - radiation effects</subject><subject>Cell Line, Tumor</subject><subject>Combined Modality Therapy</subject><subject>Cyclin-Dependent Kinase Inhibitor p21 - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Farnesyltranstransferase - antagonists &amp; inhibitors</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - enzymology</subject><subject>Glioblastoma - pathology</subject><subject>Glioblastoma - radiotherapy</subject><subject>HSP40 Heat-Shock Proteins - metabolism</subject><subject>HSP40 Heat-Shock Proteins - physiology</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Quinolones - pharmacology</subject><subject>Radiation-Sensitizing Agents - pharmacology</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9O3DAQh62qqGyBR6DyqbeAJ_7LES20tEIgIe7WJLFZoyQOtldo-yg8bZOyao89eSx985sZfYScAjsDkOacMWYqKXR9tr68q5iqGBj5gaxAclNpIeRHsvrLHJLPOT_PXwlMfiKHoAwYJWFF3m6uflY1xUyRFkxPrlAfE03YhZjdmEMJv7CEONLo6VMfYtNjLnFAOmz7EmZ2cLR1fZ9ps6Nl46jHNLq860vCMXuXMDsaxk1oQpmDH-bltdYUx-4PnWLvluilniQ_n2qgE5bNK-6OyYHHPruT_XtEHr9dP65vqtv77z_Wl7dVK4wslb4QrHGKSaZViy3WwAUTHeedAW7ajgvtFXiUHpVweMGwazU3qjFagwB-RL6-x04pvmxdLnYIebkIRxe32SozZwvzfxB0rZbrZlC-g22KOSfn7ZTCgGlngdlFnl3E2EWMneVZpuwib-77sh-wbQbX_eva2-K_AaWPlY4</recordid><startdate>20060701</startdate><enddate>20060701</enddate><creator>Wang, Chun-Chieh</creator><creator>Liao, Yu-Pei</creator><creator>Mischel, Paul S</creator><creator>Iwamoto, Keisuke S</creator><creator>Cacalano, Nicholas A</creator><creator>McBride, William H</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20060701</creationdate><title>HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway</title><author>Wang, Chun-Chieh ; Liao, Yu-Pei ; Mischel, Paul S ; Iwamoto, Keisuke S ; Cacalano, Nicholas A ; McBride, William H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-7940be605076caca213404d33d8138cd347f61fa5fa64ea90adc7386b8771413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Cell Cycle - drug effects</topic><topic>Cell Cycle - radiation effects</topic><topic>Cell Line, Tumor</topic><topic>Combined Modality Therapy</topic><topic>Cyclin-Dependent Kinase Inhibitor p21 - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Farnesyltranstransferase - antagonists &amp; inhibitors</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - enzymology</topic><topic>Glioblastoma - pathology</topic><topic>Glioblastoma - radiotherapy</topic><topic>HSP40 Heat-Shock Proteins - metabolism</topic><topic>HSP40 Heat-Shock Proteins - physiology</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Quinolones - pharmacology</topic><topic>Radiation-Sensitizing Agents - pharmacology</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Chun-Chieh</creatorcontrib><creatorcontrib>Liao, Yu-Pei</creatorcontrib><creatorcontrib>Mischel, Paul S</creatorcontrib><creatorcontrib>Iwamoto, Keisuke S</creatorcontrib><creatorcontrib>Cacalano, Nicholas A</creatorcontrib><creatorcontrib>McBride, William H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Chun-Chieh</au><au>Liao, Yu-Pei</au><au>Mischel, Paul S</au><au>Iwamoto, Keisuke S</au><au>Cacalano, Nicholas A</au><au>McBride, William H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2006-07-01</date><risdate>2006</risdate><volume>66</volume><issue>13</issue><spage>6756</spage><epage>6762</epage><pages>6756-6762</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><abstract>Resistance of glioblastoma multiforme to radiotherapy poses a major clinical challenge. Farnesyltransferase inhibitors (FTI), such as R115777, have potential to increase radiotherapeutic benefit in this disease, although their mechanism of action is unclear. In our study with eight glioblastoma multiforme cell lines, the most sensitive ones underwent cell cycle arrest in response to FTI treatment. Radiosensitization by FTIs, however, seemed to involve other pathways. If R115777 treatment was initiated &lt; 6 hours before irradiation, all eight glioblastoma multiforme lines were radiosensitized. However, if the time between drug and radiation was extended to 24 hours, cells harboring wild type but not mutated p53 were able to counteract drug-induced radiosensitization. The involvement of the p53/p21 pathway in the development of resistance was confirmed by showing that U87 cells transfected with human papillomavirus E6 to block p53 or interfering RNA to inhibit p21 stayed radiosensitive for 24 hours after drug treatment. The time dependency of R115777-induced radiosensitization suggested that the initial FTI target for early radiosensitization was short-lived, and that a p21-directed pathway restored resistance. Consideration of prenylated molecules that could potentially be involved led us to consider HDJ-2, a co-chaperone of heat shock protein 70. This hypothesis was strengthened by finding that cellular radiosensitivity was increased by genetic inhibition of HDJ-2, whereas overexpression conferred radioresistance. Importantly, irradiation of cells caused HDJ-2 to migrate from the cytoplasm to the nucleus, and this migration was inhibited by prior FTI treatment. These results have clinical relevance in that they help explain the variability in responses to FTIs that occurs following radiotherapy and elucidate some of the reasons for the complexity underlying FTI-induced radiosensitization.</abstract><cop>United States</cop><pmid>16818651</pmid><doi>10.1158/0008-5472.CAN-06-0185</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2006-07, Vol.66 (13), p.6756-6762
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_68605481
source MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Cell Cycle - drug effects
Cell Cycle - radiation effects
Cell Line, Tumor
Combined Modality Therapy
Cyclin-Dependent Kinase Inhibitor p21 - metabolism
Enzyme Inhibitors - pharmacology
Farnesyltranstransferase - antagonists & inhibitors
Glioblastoma - drug therapy
Glioblastoma - enzymology
Glioblastoma - pathology
Glioblastoma - radiotherapy
HSP40 Heat-Shock Proteins - metabolism
HSP40 Heat-Shock Proteins - physiology
Human papillomavirus
Humans
Quinolones - pharmacology
Radiation-Sensitizing Agents - pharmacology
Tumor Suppressor Protein p53 - metabolism
title HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A28%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HDJ-2%20as%20a%20target%20for%20radiosensitization%20of%20glioblastoma%20multiforme%20cells%20by%20the%20farnesyltransferase%20inhibitor%20R115777%20and%20the%20role%20of%20the%20p53/p21%20pathway&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Wang,%20Chun-Chieh&rft.date=2006-07-01&rft.volume=66&rft.issue=13&rft.spage=6756&rft.epage=6762&rft.pages=6756-6762&rft.issn=0008-5472&rft.eissn=1538-7445&rft_id=info:doi/10.1158/0008-5472.CAN-06-0185&rft_dat=%3Cproquest_cross%3E68605481%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17261157&rft_id=info:pmid/16818651&rfr_iscdi=true